Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study Decline in FVC over 52 weeks decreas
Tweet Content
Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study
Decline in FVC over 52 weeks decreased by 57% on nintedanib
But am I also just seeing a study FVC decline even with nintedanib?
@RheumNow #ACR23 Abs#2594 https://t.co/3h4mhm0ceU
Show on Archive Page
On
Display in Search Results
On
PDQ
Off